[go: up one dir, main page]

MX2009012506A - Composiciones, sintesis, y metodos para utilizar agentes antipsicoticos atipicos basados en quinolinona. - Google Patents

Composiciones, sintesis, y metodos para utilizar agentes antipsicoticos atipicos basados en quinolinona.

Info

Publication number
MX2009012506A
MX2009012506A MX2009012506A MX2009012506A MX2009012506A MX 2009012506 A MX2009012506 A MX 2009012506A MX 2009012506 A MX2009012506 A MX 2009012506A MX 2009012506 A MX2009012506 A MX 2009012506A MX 2009012506 A MX2009012506 A MX 2009012506A
Authority
MX
Mexico
Prior art keywords
synthesis
compositions
methods
atypical antipsychotic
antipsychotic agents
Prior art date
Application number
MX2009012506A
Other languages
English (en)
Inventor
Laxminarayan Bhat
Prabhu P Mohapatra
Seema Rani Bhat
Original Assignee
Reviva Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reviva Pharmaceuticals Inc filed Critical Reviva Pharmaceuticals Inc
Publication of MX2009012506A publication Critical patent/MX2009012506A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

La presente invención proporciona derivados novedosos de quinolinona que pueden utilizarse ventajosamente para tratar la esquizofrenia y psicosis relacionadas tales como desorden bipolar maniaco agudo, desorden autista, y depresión.
MX2009012506A 2007-05-21 2008-05-21 Composiciones, sintesis, y metodos para utilizar agentes antipsicoticos atipicos basados en quinolinona. MX2009012506A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93926207P 2007-05-21 2007-05-21
PCT/US2008/064433 WO2008144764A1 (en) 2007-05-21 2008-05-21 Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents

Publications (1)

Publication Number Publication Date
MX2009012506A true MX2009012506A (es) 2009-12-09

Family

ID=40072982

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009012506A MX2009012506A (es) 2007-05-21 2008-05-21 Composiciones, sintesis, y metodos para utilizar agentes antipsicoticos atipicos basados en quinolinona.

Country Status (13)

Country Link
US (1) US8247420B2 (es)
EP (1) EP2162135A4 (es)
JP (1) JP5466147B2 (es)
CN (1) CN101754761B (es)
AU (1) AU2008254585B2 (es)
BR (1) BRPI0811844A2 (es)
CA (1) CA2688784A1 (es)
IL (1) IL202003A (es)
MX (1) MX2009012506A (es)
NZ (1) NZ582124A (es)
RU (1) RU2497819C2 (es)
WO (1) WO2008144764A1 (es)
ZA (1) ZA200908753B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2400968T3 (pl) * 2009-02-26 2017-04-28 Reviva Pharmaceuticals, Inc. Kompozycje, synteza i sposoby zastosowania pochodnych arylopiperazyny
PT2445502T (pt) 2009-06-25 2017-09-22 Alkermes Pharma Ireland Ltd Compostos heterocíclicos para o tratamento de distúrbios neurológicos e psicológicos
PL395469A1 (pl) 2011-06-29 2013-01-07 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Pochodne indoloamin do leczenia chorób osrodkowego ukladu nerwowego
CN107206007B (zh) 2015-01-12 2021-08-10 雷维瓦药品公司 用于治疗肺高血压的方法
CN106749219A (zh) * 2015-11-20 2017-05-31 江苏恩华药业股份有限公司 一种内酰胺类衍生物及其应用
RU2667954C2 (ru) * 2016-03-04 2018-09-25 Общество С Ограниченной Ответственностью "Валентек" Фармацевтическая композиция для лечения функциональных психических расстройств
CN110831584B (zh) * 2017-05-04 2023-03-10 埃克塞瓦有限责任公司 具有新颖的组合物、组合的靶向药物拯救及其方法
WO2018234808A1 (en) 2017-06-22 2018-12-27 Curadev Pharma Limited Small molecule modulators of human sting
JP2020524717A (ja) * 2017-06-22 2020-08-20 キュラデブ・ファーマ・リミテッドＣｕｒａｄｅｖ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ ヒトｓｔｉｎｇの小分子調節因子
AU2019230014B2 (en) 2018-03-05 2024-11-28 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CN115784983B (zh) * 2022-12-05 2024-09-27 井冈山大学 6-胺烷氧基-3,4-二氢喹啉酮衍生物及制备方法和应用
CN116496234B (zh) * 2023-02-09 2024-09-13 江苏润安制药有限公司 一种盐酸乌拉地尔关键中间体的制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
JPS54130587A (en) * 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
JPS5649361A (en) * 1979-09-28 1981-05-02 Otsuka Pharmaceut Co Ltd Carbostyril derivative
JPS5649364A (en) * 1979-09-28 1981-05-02 Otsuka Pharmaceut Co Ltd Carbostyril derivative
CN85108214A (zh) * 1984-11-22 1986-08-20 赫彻斯特股份公司 新的取代的苯基哌嗪衍生物及其药物的制造方法
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JP2608788B2 (ja) * 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5776959A (en) * 1995-06-05 1998-07-07 Washington University Anticonvulsant and anxiolytic lactam and thiolactam derivatives
EP0900792B1 (en) 1997-09-02 2003-10-29 Duphar International Research B.V Piperazine and piperidine derivatives as 5-HT1A and dopamine D2-receptor (ant)agonists
EP1133299A1 (en) 1998-11-23 2001-09-19 Sepracor Inc. 2-hydroxymethylolanzapine compositions and methods
US6432985B2 (en) * 2000-04-25 2002-08-13 Hoffmann-La Roche Inc. Neuroprotective substituted piperidine compounds with activity as NMDA NR2B subtype selective antagonists
US6521623B1 (en) * 2000-09-19 2003-02-18 Boehringer Ingelheim Pharma Kg N,N'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors
SE0200301D0 (sv) 2002-02-01 2002-02-01 Axon Biochemicals Bv Thio-carbostyril derivative
AU2003226737B2 (en) * 2002-03-29 2008-09-04 Janssen Pharmaceutica N.V. Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands
TWI312781B (en) 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
UA77526C2 (en) * 2002-06-07 2006-12-15 Sanofi Aventis Substituted derivatives of 1-piperazineacylpiperidine, a method for the preparation thereof and their use in therapy
AU2003263413A1 (en) * 2002-09-17 2004-04-08 Warner-Lambert Company Llc Heterocyclic substituted piperazines for the treatment of schizophrenia
DE60302139T3 (de) 2003-01-09 2011-02-24 Otsuka Pharmaceutical Co., Ltd. Verfahren zur herstellung von aripiprazole
TWI289141B (en) 2003-03-11 2007-11-01 Hoffmann La Roche F. Ag. Quinolinone derivatives and uses thereof
CA2428237C (en) 2003-05-08 2010-07-20 Delmar Chemicals Inc. Process for the preparation of carbostyril derivatives
UA92453C2 (ru) * 2003-05-23 2010-11-10 Оцука Фармасьютикел Ко., Лтд. Производные карбостирила и стабилизаторы настроения для лечения расстройств настроения
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
EP1797039A1 (en) 2004-09-13 2007-06-20 Matrix Laboratories Ltd Process for the preparation of polymorphs, solvates of aripiprazole using aripiprazole acid salts
NZ554731A (en) 2004-10-08 2009-12-24 Suven Life Sciences Ltd Novel Intermediates Useful For The Preparation Of Aripiprazole And Methods For The Preparation Of The Novel Intermediates And Aripiprazole

Also Published As

Publication number Publication date
JP2010528042A (ja) 2010-08-19
RU2497819C2 (ru) 2013-11-10
ZA200908753B (en) 2010-07-28
EP2162135A4 (en) 2012-02-22
US8247420B2 (en) 2012-08-21
RU2009147268A (ru) 2011-06-27
IL202003A (en) 2013-11-28
US20080293736A1 (en) 2008-11-27
NZ582124A (en) 2012-07-27
IL202003A0 (en) 2010-06-16
BRPI0811844A2 (pt) 2014-11-18
CN101754761B (zh) 2014-06-18
WO2008144764A1 (en) 2008-11-27
AU2008254585A1 (en) 2008-11-27
AU2008254585B2 (en) 2013-09-26
CN101754761A (zh) 2010-06-23
CA2688784A1 (en) 2008-11-27
EP2162135A1 (en) 2010-03-17
JP5466147B2 (ja) 2014-04-09

Similar Documents

Publication Publication Date Title
MX2009012506A (es) Composiciones, sintesis, y metodos para utilizar agentes antipsicoticos atipicos basados en quinolinona.
MY161473A (en) Compositions, synthesis, and methods of utilizing arylpiperazine derivatives
EA201071234A1 (ru) Производные изохинолинона в качестве nk3 антагонистов
MX2011009568A (es) Inhibidores de la rho cinasa.
JO2788B1 (en) Amido phenoxyendazole compounds beneficial as C-MET inhibitors
MY153915A (en) Organic compounds
PH12012500674A1 (en) Heterocyclic compounds useful as pdk1 inhibitors
MX2011001679A (es) Derivados de flavina.
MX354402B (es) Inhibidores de molecula pequeña del dominio de homologia de pleckstrin y metodos para usar los mismos.
MX2010003366A (es) Derivados de piperidina y piperazina para el tratamiento de tumores.
MY152749A (en) Pyrazole and fused pyrazole glucokinase activators
GEP20125652B (en) cMET INHIBITORS
AU2011278832A8 (en) Novel fused heterocyclic derivatives useful as c-Met tyrosine kinase inhibitors
PT2470546E (pt) Compostos de hexa-hidrooxazinopteridina para serem utilizados como inibidores de mtor
ATE548374T1 (de) 2'-fluor-2'-desoxytetrahydrouridine als cytidindeaminaseinhibitoren
CY1113680T1 (el) Ενωσεις πυραζινης ως αναστολεις φωσφοδιεστερασης 10
TW201713640A (en) Bruton's tyrosine kinase inhibitors
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
WO2009117676A3 (en) Novel piperidine derivatives as inhibitors of stearoyl-coa desaturase
MX2012002366A (es) Agonistas novedosos de receptores beta 3 andrenergicos derivados de pirrolidina.
GB2466912A (en) Compositions and methods for treating lysosomal disorders
MX2010003365A (es) Derivados de tiazol para el tratamiento de cancer.
NI200900153A (es) Nuevo procedimiento de síntesis de la agomelatina.
MX2009013515A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica.
WO2010027424A3 (en) 9-substituted phenanthrene based tylophorine derivatives

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration